🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our CEO Paul Bresge will be speaking on Oct 5 at Lotte NY Palace in NYC at  3 pm - Rewriting the Code: Navigating the Frontier of Gene & Cell Therapy Lei Lei Wu Endpoints News will be moderating the panel. Other panelists include JURA Bio, Inc. Aurion Biotech Immusoft Corporation Excision BioTherapeutics

Happy #NewMemberMonday! 🥼Experic Services is a CDMO focused on the needs of small, midsize & specialty pharmas 🏢KingStreetProperties removes real estate obstacles for science companies 👁️Ray Therapeutics, Inc. is on a mission to restore vision with the power of optogenetics

Our Chief Development Officer jenny holt speaks with BioProcess Online and Forge Biologics about #CDMOs and what’s constitutes a good partnership. Listen here: 👇👇👇 bioprocessonline.com/doc/cdmo-emerg…

Excited to announce we’ve been awarded $4M by California Institute for Regenerative Medicine to develop RTx-021 for the treatment of geographic atrophy age-related macular degeneration. Read the full release: businesswire.com/news/home/2023…

Ray Therapeutics secures $4M from CIRM to develop optogenetic therapy treatment for geographic atrophy Ray Therapeutics, Inc. #Funding #BioTech #Startups #optogenetics #CIRM #optogenetic #therapy #BreakingNews #Breaking techstartups.com/2023/11/13/ray…

Congratulations Paul Bresge & team! "The treatment delivers light sensing channel rhodopsin to retinal cells, to potentially restore vision using the power of #optogenetics"

Ray Therapeutics Receives $4 Million in Funding from the California Institute for Regenerative Medicine to Advance Optogenetic Therapy buff.ly/49DKuSr

🟢Cell therapy weekly: Ray Therapeutics, Inc. has been awarded US$4 million grant to advance optogenetic therapy Legend Biotech and Novartis form partnership a strategic partnership InGeneron reports positive data for rotator cuff tear cell therapy!

.BioWorld covers our recent funding from California Institute for Regenerative Medicine: bioworld.com/articles/70281…

.RegMedNet covers our funding news from California Institute for Regenerative Medicine: regmednet.com/cell-therapy-w…

💡JPM 2024 Featured Session with Jenny Holt (Ray Therapeutics, Inc.), Chris McDonald (Kite, a Gilead Company), A Gilead Company, Morten Sogaard (@AstellasGeneTx), and Brian Riley (Beam Therapeutics) Register Here: lnkd.in/eTsmh7Pc #FierceJPMWeek #JPMWeek

This week's podcast features industry leaders sharing valuable insights on early commercial strategy and navigating the journey from regulatory approval to commercialization. This #OISXIII panel is a must-listen for anyone in the industry! Listen Now: ois.net/insights-from-…

"You're going blind, there's nothing that can be done." Motivation for Paul Bresge to launch jCyte & Ray Therapeutics, Inc. to find cure for #retinitispigmentosa, the blinding disease his daughter Tamar was diagnosed with. Story by Mollie Barnes ✍🏻 in BioSpace biospace.com/article/how-a-…

.@surfernan speaks with our CEO Paul Bresge for Raising Biotech podcast. Listen here: #optogenetics shows.acast.com/raisingbiotech…

Our Chief Development Officer Jenny Holt is speaking at LSX Leaders #LSXCongress in Boston today at 11 am ET. Check out the agenda: informaconnect.com/lsx-world-cong…

Our CEO Jenny Holt moderated a great session today at LSX Leaders in Boston. Thanks to all the panelists and everyone who attended the session!

We’re thrilled to welcome Christopher Whitmore as CFO. Mr. Whitmore is a highly accomplished executive who brings over 20 years of strategic finance, accounting, and operational expertise to our team. Read the release: businesswire.com/news/home/2024…

CIRM has awarded nearly $8 million to Ray Therapeutics, Inc. to support a Phase 1 clinical trial for retinitis pigmentosa (RP), a rare, degenerative eye disease with no cure. This marks the 116th CIRM-funded clinical trial. cirm.ca.gov/about-cirm/new…